


## Data Sheet

---

<b>Product Name:</b>	STK16-IN-1
<b>Cat. No.:</b>	CS-6463
<b>CAS No.:</b>	1223001-53-3
<b>Molecular Formula:</b>	C <sub>17</sub> H <sub>12</sub> FN <sub>3</sub> O
<b>Molecular Weight:</b>	293.30
<b>Target:</b>	Others
<b>Pathway:</b>	Others
<b>Solubility:</b>	DMSO : 15 mg/mL (ultrasonic;warming)



### BIOLOGICAL ACTIVITY:

STK16-IN-1 is a **STK16** kinase inhibitor with an **IC<sub>50</sub>** of 295 nM. **IC<sub>50</sub>** & Target: **IC<sub>50</sub>**: 295 nM (STK16)<sup>[1]</sup> *In Vitro*: STK16-IN-1, which exhibits potent inhibitory activity against STK16 kinase (**IC<sub>50</sub>**=0.295  $\mu$ M) with excellent selective across the kinome as assessed using the KinomeScanTM profiling assay. STK16-IN-1 inhibits mTOR kinase with an **IC<sub>50</sub>** of 5.56  $\mu$ M. In MCF-7 cells, treatment with STK16-IN-1 results in a reduction in cell number and accumulation of binucleated cells, which can be recapitulated by RNAi knockdown of STK16. Co-treatment of STK16-IN-1 with chemotherapeutics such as cisplatin, doxorubicin, colchicine and paclitaxel results in a slight potentiation of the anti-proliferative effects of the chemotherapeutics. STK16-IN-1 provides a useful tool compound for further elucidating the biological functions of STK16<sup>[1]</sup>.

### PROTOCOL (Extracted from published papers and Only for reference)

**Kinase Assay:** <sup>[1]</sup>STK16-IN-1 is generally prepared with 1:3 serial dilutions for 4 concentrations (100 nM, 50 nM, 20 nM, and 10 nM); 6 concentrations are used (1 mM to 10  $\mu$ M) for ATP competition experiments. The kinase reaction is performed with 1×kinase reaction buffer. Reactions in each well are started immediately by adding ATP and kept going for half an hour under 37°C. After the plate cooled for 5 minutes at room temperature, 5  $\mu$ L of ADP-Glo reagent is added into each well to stop the reaction and consume the remaining ADP within 40 minutes. At the end, 10  $\mu$ L of kinase detection reagent is added into the well and incubated for 1 hour to produce a luminescence signal<sup>[1]</sup>. **Cell Assay:** <sup>[1]</sup>MCF-7, HCT116, HeLa cells are treated with STK16-IN-1 (0, 5, 10  $\mu$ M) for 72 hours and apoptotic cells are analyzed by flow cytometry using Annexin V/PI apoptosis detection kit<sup>[1]</sup>.

### References:

[1]. Liu F, et al. Discovery of a Highly Selective STK16 Kinase Inhibitor. ACS Chem Biol. 2016 Jun 17;11(6):1537-43.

### CAIndexNames:

2H-Pyrrolo[2,3-h]-1,6-naphthyridin-2-one, 1-(4-fluoro-3-methylphenyl)-1,7-dihydro-

### SMILES:

FC1=CC=C(N2C(C=C2=O)=CN3)=C4C3=NC=C4)C=C1C

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 610-426-3128

Fax: 888-484-5008

E-mail: sales@ChemScene.com

Address: 1 Deer Park Dr, Suite F, Monmouth Junction, NJ 08852, USA